Ting Zhou

Ting Zhou

New York P +1 (212) 415-9373 F +1 (646) 417-7259



Ting is a partner in Dorsey & Whitney’s corporate group and a member of the firm’s globally recognized U.S.-China practice group. Ting has been practicing for more than 15 years with top law firms in the U.S. and China, and has gained sophisticated experience in dealing with complicated projects. Her legal skills and experience in practicing both the U.S. law and Chinese law have enabled her to well serve clients’ growing cross-border legal needs and help clients achieve their business goals. She has advised clients ranging from Fortune 500 companies, private equity and venture capital funds to entrepreneurs and scientists.

Ting represents clients in domestic and cross border M&A transactions, both sell- and buy-side, startup formations and financings, private equity fund formations, strategic investments into industries and technology areas that represent the future economy, and also counsels clients in a variety of general corporate matters.

In addition to her transactional experience, Ting also works closely with our litigation teams in litigation prevention and risk management for corporate transactions, as well as in product liability defense matters.

Education & Admissions

Columbia Law School (LL.M., 2015), James Kent Scholar

East China University of Politics and Law (LL.B., 2005)


  • New York


  • English, Mandarin


Representative Work

Corporate Transactions – Greenfield Investments, M&As, Startup Financings, JVs, and Investments

  • Represented various companies in the solar, EV battery and related clean energy industries in their site selection and greenfield investments in the U.S.
  • Advised The Coca-Cola Company with respect to the complex reorganization of Coca-Cola Bottlers Manufacturing Holdings Limited (“CCBMH”). CCBMH, a joint venture entity founded by The Coca Cola Company (through two subsidiaries) and subsidiaries of Swire Group and COFCO (China’s largest state-owned food and agriculture company), through multiple subsidiaries provides preparation and packaging operations in relation to Coca Cola’s still beverages business across Mainland China. On completion of the transaction, the multiple subsidiaries of CCBMH in Mainland China will be transferred to and owned by Swire Group and COFCO, respectively, and The Coca-Cola Company will start its franchise partnership with Swire and COFCO regarding the still beverage bottling system in Mainland China.
  • Advised Guangzhou R&F Properties Co., Ltd. in the disposal of its remaining 30% equity interest in Guangzhou International Airport R&F Integrated Logistics Park with the property value at approximately RMB 7.3 billion (US$1.14 billion) to The Blackstone Group Inc. 
  • Represented Eddingpharm Group, a leading pharmaceutical contract sales company in China, in connection with its acquisition of certain pharmaceutical product rights in China from Eli Lilly.
  • Represented H. J. Baker Sulphur Holdings, LLC in its acquisition and financing of Oxbow Sulphur Inc. and its worldwide sulphur business affiliates.
  • Represented a restaurant chain company in its group reorganization, business expansion, franchise, and other various corporate matters.
  • Represented Yili Group, the largest dairy products company in Asia, in its bidding for Stonyfield, the No. 1 organic yogurt maker in the United States, a subsidiary of Danone.
  • Represented CDH Investments, a top Chinese PE firm, in connection with multiple acquisitions and investments.
  • Represented a New York based IVF clinic center in its separation of non-clinical assets and receiving investments from international investors.
  • Represented a leading non-profit biomedical research organization in the United States in connection with its proposed joint venture and collaborative research initiatives with business partners and universities in China.
  • Represent founders in forming biotech group companies and receiving $25 million in the initial round of financing.
  • Represented multiple pharmaceutical and biotech companies in securing debt and equity financings, encompassing a range of instruments such as SAFE agreements, Series Seed, convertible notes, and Series A, B, and C rounds of financing.
  • Represented a Hong Kong Stock Exchange listed real estate conglomerate in connection with its acquisitions of multiple real estate portfolios in the United States, including retirement living facilities, student housing projects and other commercial and mixed use properties.
  • Represented certain shareholders of a Minnesota-based private marketing and sales company in the proposed sale of their controlling interests in the company to a Chinese public company.
  • Represented a U.S. maritime technology company in its sale to a Beijing-based Chinese public company.
  • Represented Johnson Controls in selling its China related automotive electronics business (a part of its global sales of automotive electronics business) to Visteon.
  • Represented a US leading auto components manufacturer, in selling part of its equity interest in a joint venture to its Chinese partner.
  • Represented a major multinational medical device manufacturer in the acquisition of its distributor.
  • Represented a leading Chinese ore processing company in its joint venture with a major Dutch company and a major US company.

General Corporate – Corporate Formation, Governance, and Commercial Contracts

  • Representing more than ten biotech companies based in California, Massachusetts, and New Jersey in various matters relating to their operations in the U.S. and cross-border commercial contracts with third parties outside of the U.S.
  • Represent multiple U.S. biotech companies in negotiation of license and commercialization agreements for vaccine technologies and products with Asian licensees.
  • Represented a leading global biopharmaceutical company in negotiation of development and commercialization agreement for two bifunctional sialidase programs with a leading U.S. biotechnology company.
  • Represented a leading Chinese specialty pharmaceutical company in the negotiation of a development and commercialization agreement for nebulized revefenacin product with a diversified biopharmaceutical company.
  • Represented a leading Chinese pharmaceutical company in the negotiation of a license agreement and a supply agreement for pulmonary surfactant product and medical device with an Irish biopharmaceutical company.
  • Represented a Chinese dental startup in the negotiation of a license agreement for invisible clear aligner with a U.S. company.
  • Counseled Ninebot Limited, a portfolio company of Xiaomi Technologies and Sequoia Capital, in its general corporate, employment, IP and other matters.
  • Represented Fantasia Group, China’s largest property management conglomerate, in its expansion and operations in the U.S.
  • Represented one of the largest dairy products companies in China in its expansion in the U.S.
  • Represented a leading infrastructure construction company in China in its expansion in the U.S.
  • Represented a Chinese consumer product manufacturer and its U.S. subsidiary in the negotiation of multiple supply agreements with U.S. customers.

Private Equity Fund – Formation and Investments

  • Represented a sponsor group in the organization of a $150 million private equity fund.
  • Represented an investment fund in its secondary transactions acquiring over $500 million of limited partner commitments.
  • Represented a family office in its investments in multiple single-investment SPV funds organized to invest in China based pre-IPO, growth-stage companies.
  • Represented a Chinese state-owned asset management company (with AUM of over RMB one trillion yuan) in its investment in a $650 million private debt fund.
  • Represented a private equity fund (with AUM of $250 million) in its reorganization.

Capital Markets

  • Represented HSBC and other underwriters for Citic Pacific (00267.HK)’ s USD 4.5 billion Euro Medium Term Notes (EMTN) Program and its updates.
  • Represented China Lodging Group, Limited (NASDAQ:HTHT), a leading economy hotel chain operator in China, on its listing on NASDAQ and its annual filing.
  • Advised shareholders of U.S. public companies on Rule 144 transactions.

Solving Problems – Risk Management, Product Liability Defense

  • Represented minority shareholders in protecting their rights and economic stakes in several controlling shareholder dominated situations.
  • Represented multiple Chinese companies in handing their disputes with U.S. distributors and customers.
  • Represented a Chinese home appliance manufacturer in handling its product recall in the U.S. and Canada, including negotiating with its U.S. distributor regarding allocation of recall liabilities, preparing responses to CPSC, implementing recall plan and coordinating with insurance carriers.
  • Represented a Chinese consumer product manufacturer in handling a potential product recall in the U.S.
  • Represented multiple Chinese manufacturers in handling their product liabilities matters in the U.S., including engaging and coordinating adjusters, negotiating settlement agreements with claimants.
Ting Zhou